Associated Papers
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
40121945 (PubMed )
Supplement: mmc5.xlsx › Ark1
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
NOS3 and CTH gene mutations as new molecular markers for detection of lung adenocarcinoma.
Abdullah Ramadhan I et al.
Peerj, 2023
38107574 (PubMed )
Supplement: peerj-11-16209-s002.xls › NOS3
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Mutational drivers of cancer cell migration and invasion.
Novikov NM et al.
British Journal of Cancer, 2021
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A et al.
Nature Communications, 2020
32839463 (PubMed )
Supplement: 41467_2020_17880_MOESM6_ESM.xlsx › Unpaired_Mutations_GBC
Precision medicine and actionable alterations in lung cancer: A single institution experience.
Mambetsariev I et al.
Plos One, 2020
32045431 (PubMed )
Supplement: pone.0228188.s005.xlsx › Sheet1
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
Kawada I et al.
Cancer Biology & Therapy, 2013
Select a paper to view details